{"filing":{"accession_number":"0001193125-26-312390","cik":"0001936258","ticker":"NAMSW","company_name":"NewAmsterdam Pharma Co N.V.","form":"8-K","filing_date":"2026-07-22","report_date":null,"primary_document":"nams-20260716.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1936258/000119312526312390/nams-20260716.htm"},"events":[{"id":19471,"run_id":17527,"accession_number":"0001193125-26-312390","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Douglas Kling, the Company's Chief Operating Officer, notified the company on July 16, 2026 of his resignation effective August 14, 2026 to join another biotech company as CEO. This is a clear executive departure of a named officer. While the filing mentions anticipated separation and advisor agreements, the principal disclosed action is Kling's departure from his COO role, making exec_departure the most salient classification.","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-07-22","form":"8-K","submitted_at":null,"items":[{"id":18567,"accession_number":"0001193125-26-312390","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Douglas Kling, the Company's Chief Operating Officer, notified the company on July 16, 2026 of his resignation effective August 14, 2026 to join another biotech company as CEO. This is a clear executive departure of a named officer. While the filing mentions anticipated separation and advisor agreements, the principal disclosed action is Kling's departure from his COO role, making exec_departure the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:06:59.715342+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":18567,"accession_number":"0001193125-26-312390","item_number":"5.02","item_title":null,"event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"Douglas Kling, the Company's Chief Operating Officer, notified the company on July 16, 2026 of his resignation effective August 14, 2026 to join another biotech company as CEO. This is a clear executive departure of a named officer. While the filing mentions anticipated separation and advisor agreements, the principal disclosed action is Kling's departure from his COO role, making exec_departure the most salient classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-22T20:06:59.715342+00:00","company_name":"NewAmsterdam Pharma Co N.V.","ticker":"NAMSW","filing_date":"2026-07-22"}]}